Myriad Genetics


Brief History

Founded in 1991, Myriad was one of the first genomic companies, driven by the vision of elucidating the role genes play in human disease and using this critical information to improve patient care by developing novel molecular diagnostic products.

  • Myriad’s molecular diagnostic products are designed to assess an individual's risk for developing disease so that action can be taken to prevent or delay its onset.
  • Our diagnostic tests help in the early and accurate diagnosis of disease, when it is more treatable and survival rates are better.
  • Our prognostic medicine products assess a patient's risk of disease progression and recurrence, so that a healthcare professional knows how aggressively to treat the disease.
  • Our companion diagnostic products identify a patient’s likelihood of responding to a particular therapy to ensure optimal treatment decisions.



Myriad and Gene Discovery

In conjunction with numerous collaborators from around the world, Myriad scientists have discovered many important disease-causing genes, including:

  • BRCA1 and BRCA2 genes associated with hereditary breast and ovarian cancer;

  • p16 cell cycle control gene that increases the risk of developing a variety of cancers, notably melanoma;

  • PTEN tumor suppressor gene that is involved in the development of many cancers;

  • ELAC2 prostate cancer gene.


Myriad Developed the First Molecular Diagnostic Test for Breast Cancer

In 1996, Myriad introduced the first molecular diagnostic test for hereditary breast and ovarian cancer. This test, BRACAnalysis ®, became the standard of care for determining a person’s risk of developing these hereditary cancers and has been followed by several other innovative molecular diagnostic tests for breast, colon, lung, pancreatic, prostate, ovarian and uterine cancers, as well as melanoma. To date, Myriad’s hereditary cancer tests have benefited more than 3 millions patients.


Protein Biomarker Solutions Have Been Added to Our Technology Portfolio

Myriad is a pioneer in applying nucleic acid (DNA and RNA) technologies to identifying novel genetic biomarkers that have the potential to save lives and improve the quality of life for patients with cancer or who have a family history of the disease. In 2011, Myriad acquired Rules-Based Medicine of Austin, Texas, a leader in using multiplex immunoassay technologies to discover protein biomarkers. The ability to work with DNA, RNA and proteins gives Myriad a complete complement of biomarker technologies and positions the Company as a leader in the emerging field of companion diagnostics and personalized medicine. Learn more about Myriad RBM.


We Have Expanded into the Area of Autoimmune Diseases

In 2014, as part of our efforts to add to our diagnostic portfolio that is focused on saving lives and improving the quality of life for patients across major diseases, Myriad acquired Crescendo Bioscience, a global leader in autoimmune diagnostics, located in South San Francisco, California.  Crescendo pioneered protein-based diagnostics for monitoring disease activity in patients with rheumatoid arthritis and has a pipeline of products under development for a wide range of autoimmune diseases and conditions.


Global Expansion and Increased Reach

In 2012, Myriad expanded internationally with the opening of our laboratory in Munich, Germany. We currently have a presence in 128 countries: 16 in which we have direct subsidiaries and 112 countries in which we have 44 distributors on 6 continents. Our international corporate headquarters is located in Zurich, Switzerland, and we have sales operations in Paris, France; Madrid, Spain; Milan, Italy; Munich and Zurich. We believe that our robust portfolio of diagnostic tests will benefit patients worldwide by assisting healthcare professionals in guiding their healthcare decisions.


Company Milestones 

July 2018 -> Myriad acquires Counsyl and enters the reproductive genetic testing market.

January 2018 -> Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for LynparzaTM in patients with metastatic breast cancer.

September 2017 -> Myriad launches riskScore® test for women tested myRisk® Hereditary Cancer.

May 2017 -> Medicare Coverage of Prolaris® expands to include men with favorable-intermediate prostate cancer. 

March 2017 -> EndoPredict® test is launched in the United States.

August 2016 -> Myriad acquires Assurex Health and the Genesight® genetic test.

May 2016 -> Myriad acquires Sividon Diagnostics, a leading breast cancer prognostic company.

October 2015 -> Myriad receives Medicare coverage of Prolaris® for prostate cancer patients.

January 2015 -> Myriad receives European CE Marking approval for its Tumor BRACAnalysis CDx test for use as a companion diagnostic to predict responders to PARP inhibitors such as LynparzaTM (olaparib).

December 2014 -> Myriad receives FDA approval for its BRACAnalysis CDx® test to identify ovarian cancer patients who may benefit from the PARP inhibitor LynparzaTM (olaparib).

October 2014 -> Myriad receives draft Medicare coverage for Prolaris®, a revolutionary test for prostate cancer. 

February 2014 -> Myriad acquires of California-based Crescendo Biosciences Inc. and diversifies into the autoimmune market. 

January 2014 -> Myriad licences EndoPredict®, a second generation prognostic test for patients diagnosed with breast cancer.

November 2013 -> Myriad launches the Myriad myPath® Melanoma diagnostic test to differentiate benign skin lessions from malignant melanoma.

October 2013 -> Myriad launches the Myriad myPlan® Lung Cancer prognostic test for patients with lung cancer. 

September 2013 -> Myriad launches Myriad myRisk® Hereditary Cancer, a 25-gene panel test for eight major cancers. 

June 2011 -> Myriad acquires Texas-based Rules Based Medicine and forms Myriad RBM®, a wholly owned subsidiary.

December 2010 -> Myriad launches PANEXIA®, a predictive test for pancreatic cancer.

November 2010 -> Crescendo Bioscience Inc. announces the launch of Vectra® DA, the first multi-biomarker blood test that measures rhematoid arthritis disease activity.

March 2010 -> Myriad launched Prolaris®, the first prognostic test to predict prostate cancer survival. 

December 2008 -> Myriad launches PREZEON®, a genetic test to assess the status of the PTEN gene.

January 2008 -> Myriad launches BRACAnalysis® for the women's health preventive care market, significantly expanding access to genetic cancer testing. 

May 2002 -> Myriad launches COLARIS AP®, a genetic test for FAP colon cancer syndrome. 

November 2001 -> Myriad launches MELARIS®, a test for melanoma

September 2000 -> Myriad launches COLARIS®, a genetic test for hereditary colorectal and uterine cancer.

March 1997 -> Myriad announces the discovery of the PTEN gene that is associated with a large number of cancers.

November 1996 -> Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market.

December 1995 -> Myriad announces the discovery of the BRCA 2 gene that is associated with hereditary breast and ovarian cancer.

October 1995 -> Myriad becomes public company and its traded on NASDAQ under the ticker: MYGN.

September 1994 -> Myriad scientists publishes in Science the discovery of the BRCA 1 gene that is associated with the hereditary breast and ovarian cancer.

Fall 1993 -> Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma 

May 1991 -> Myriad Genetics Inc. is founded, making it one of the first genomics companies in history.



Terms of Use

The following terms apply to the web site. The web site is owned and operated by Gene Analysis.


Contact info